AbbVie Lifts Profit Outlook as Inflammatory Drugs Rinvoq and Skyrizi ...
AbbVie Lifts Profit Outlook as Inflammatory Drugs Rinvoq and Skyrizi ...
AbbVie Reports First-Quarter 2020 Financial Results
Global SKYRIZI net revenues were $300 million and global RINVOQ net revenues were $86 million . On a GAAP basis, the gross margin ratio in the ...
Form 10-K for Abbvie INC filed 02/17/2023
... medicines within the JAK inhibitor class for the treatment of inflammatory diseases, including Rinvoq. Confirming the recommenda on from the ...
AbbVie Reports First-Quarter 2020 Financial Results
• First-Quarter Global SKYRIZI Net Revenues Were $300 Million; Global RINVOQ Net Revenues Were $86 ... profit forecast for the purposes of ...